Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Solifenacin improves urinary symptoms but worsens constipation in MS patients with OAB

22 Sep 2020

In the treatment of multiple sclerosis (MS) patients with overactive bladder (OAB) symptoms, mirabegron and solifenacin yield similar response rates, with the latter producing a greater decrease in urinary symptom severity but exerting a less favourable effect on constipation, a study has found.

The study included 61 MS patients who had not received treatment for their OAB symptoms. Patients enrolled in years 1–2 were administered mirabegron, whereas those enrolled in years 3–4 were prescribed solifenacin. All of them completed the OAB Questionnaire Short Form (OAB-q SF) and Patient Assessment of Constipation Symptoms (PAC-SYM) at baseline and 6-week follow-up.

A similar number of patients in the mirabegron and the solifenacin groups achieved the primary outcome of minimal clinically important difference (MCID) in OAB-q SF symptom severity (70 percent vs 69 percent, respectively).

However, patients on solifenacin showed a significantly greater improvement in the OAB-q SF score at the end of the study (−37.87 vs −20.43; p=0.02).

Meanwhile, constipation improved in the mirabegron group and worsened in the solifenacin group (change in PAC-SYM, −0.38 vs 0.22; p=0.02), and 30 percent of patients who were prescribed the latter experienced worsening above the MCID threshold.

Although there is short-term evidence of a more favourable improvement in urinary symptom severity with solifenacin, this potential benefit must be weighed against the observed risk of worsening constipation, according to researchers. Additional investigation is required to confirm these findings.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.